UGT1AI*6 and UGT1A1*27 for individualized irinotecan chemotherapy.

摘要: Genetic polymorphisms of uridine 5'-diphospho-glucuronosyl-transferase (UGT)1A1, a crucial drug-metabolizing enzyme the anticancer drug irinotecan, are essential determinants individual variation in susceptibility to irinotecan-related toxicity. The FDA has revised package insert irinotecan order warn association between toxicity and UGTIA1*28, variant sequence promoter region UGTIA1 gene. Unlike UGT1A1*28, UGT1AI*6 UGTIA1*27 found coding gene, known directly reduce activity UGT enzyme. Therefore, it is reasonable assume that presence UGT1A1*6 or would also increase risk Importantly, UGTIA1*6 UGT1Al*27 have only been identified Asian population. Although conclusive evidence linking UGTIAI*6 and/or insufficient at this time, these variants should be tested addition UGTIA1*28 for more individualized chemotherapy, especially among